The European Commission (EC) today announced it has secured over 10,000 treatment courses of tecovirimat to treat monkeypox.
SIGA Technologies’ (Nasdaq: SIGA) tecovirimat, sold under the trade name TPOXX, is authorized for use to treat smallpox, monkeypox and cowpox in the European Union. The company’s shares rose as much as 4% to $10.70 following the announcement
This emergency procurement is funded by the Health Emergency Preparedness and Response Authority (HERA) and channelled via rescEU to treat patients in member states with immediate needs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze